Diovan Sales Data
| Rank 23 | Current sales rank, all U.S. Pharmaceuticals. |
Last updated: February 2014 (updated quarterly).
The following data shows Diovan U.S. retail sales in Q4 2013 compared to previous quarters.
| Date Range | Sales Rank | Sales ($000) | Units (000) | ||
|---|---|---|---|---|---|
| Q4 2013 | 23 | $533,924 | 2.80% | 1,661 | -3.65% |
| Q3 2013 | 23 | $519,382 | -2.52% | 1,724 | -8.25% |
| Q2 2013 | 23 ( 3) |
$532,798 | -0.99% | 1,879 | -2.29% |
| Q1 2013 | 20 ( 3) |
$538,141 | 13.39% | 1,923 | 1.75% |
| Q4 2012 | 23 (1) |
$474,603 | 1.13% | 1,890 | -2.88% |
| Q3 2012 | 24 (1) |
$469,299 | -4.29% | 1,946 | -4.00% |
| Q2 2012 | 25 | $490,315 | -3.79% | 2,027 | -3.43% |
| Q1 2012 | 25 (3) |
$509,615 | 12.44% | 2,099 | -1.64% |
| Q4 2011 | 28 (1) |
$453,233 | 0.69% | 2,134 | 1.43% |
| Q3 2011 | 27 (2) |
$450,115 | -9.44% | 2,104 | -8.44% |
| Q2 2011 | 25 (1) |
$497,049 | 5.84% | 2,298 | -1.03% |
| Q1 2011 | 26 | $469,639 | n/a | 2,322 | n/a |
* Units refer to the number of packages sold.
Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.
